Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Slides:

Advertisements

Similar presentations

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

Advertisements

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis Karin Birkenkamp-Demtröder, Emil Christensen,

Dose-escalation patient response.

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Volume 73, Issue 4, Pages (April 2018)

Figure 3 Monitoring clonal evolution using liquid biopsies

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

A, baseline and 4-week PET scan from patient 2 (MET c

Volume 147, Issue 4, Pages (April 2015)

by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff

Anna F. Farago, MD, PhD, Long P

Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

AKT dependence of ovarian cancer cell lines.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Anna F. Farago, MD, PhD, Long P

Emerging Targets for the Diagnosis of Cancer

Obesity and type 2 diabetes forecasts.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

How Can Precision Medicine in Oncology Refine Best Treatment Approach?

Hospital-level procedural sedation rates among pediatric patients in the earliest year, (2009, red circle) and the most recent year (2014, blue bar). Hospital-level.

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Figure 1. Overview of BEECH study exploratory analysis

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Biochemical and behavioral assessment of GRIN2B(P553T) patient after l-serine dietary supplementation. Biochemical and behavioral assessment of GRIN2B(P553T)

Identifying TRK Fusions in Head and Neck Cancer

ALK resistance mutations predict for sensitivity to lorlatinib in patient-derived cell line models of acquired resistance to ceritinib. ALK resistance.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Integrated mRNA and microRNA expression and DNA methylation clusters.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Plasma and tissue EGFR allele analyses.

Duration of treatment and intervals of radiographic and ctDNA response

Cytotoxic effect of BET inhibition in malignant B-cell lines and CLL patient-derived B cells is independent of survival signals. Cytotoxic effect of BET.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

The long tail of mutational hotspots in cancer.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Location of the ER mutations and frequencies per cohort.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Representative patient responses to ulixertinib.

Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.

Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to.

Genomic determinants of response to cytotoxic chemotherapy.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

BRAF in-frame deletion confers response to MAPK inhibition.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

Resistance to entrectinib in xenopatient and colorectal cancer cell models carrying NTRK1 translocations. Resistance to entrectinib in xenopatient and.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Balancing bleeding in brain metastases

Mutant TERT promoter displays active histone marks and distinct long-range interactions: A, cell lines that were used in the study with their origin and.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Therapeutic efficacy of MEK and RAF inhibition in patients with MAP2K1- and ARAF-mutant systemic histiocytic neoplasms. Therapeutic efficacy of MEK and.

TRK inhibitor binding to acquired resistance mutations.

Presentation transcript:

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Top, CT scans of a patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement were recorded at baseline (March 2014), at the time of partial response to the pan-TRK inhibitor entrectinib (April 2014), and upon disease progression (July 2014). Bottom, longitudinal analysis of plasma ctDNA collected at different time points throughout the treatment. Red bars, absolute LMNA–NTRK1 copies in 1 mL of plasma; blue and black lines, NTRK1 p.G595R- and p.G667C-mutated alleles (%), respectively. Average ± SD of 3 independent experiments is reported. Mariangela Russo et al. Cancer Discov 2016;6:36-44 ©2016 by American Association for Cancer Research